Taga Saeko, Asano Hiroki, Iwai Mina, Takenaka Shoya, Moriya Akihiro, Otsuka Takashi, Kimura Michio, Yoshimura Tomoaki
Dept. of Pharmacy, Ogaki Municipal Hospital.
Gan To Kagaku Ryoho. 2022 Oct;49(10):1093-1097.
A new nivolumab and pembrolizumab monotherapy regimen with double the conventional dose and longer dosing intervals( the new regimen)has been approved. Here, we report the incidence of immune-related adverse events(irAEs)in the early phase of switching from the conventional regimen to the new regimen at Ogaki Municipal Hospital. Thirty-seven patients switched to the new regimen between October 2020 and February 2021: 7(18.9%)switched to nivolumab and 5 (14.3%)to pembrolizumab. Two of the 7 patients treated with nivolumab developed irAEs. One patient developed Grade 3 colitis on day 51 following the switch to the new regimen, and the treatment was discontinued. The other patient developed Grade 3 adrenal insufficiency on day 72 and was hospitalized. No irAEs were observed with pembrolizumab treatment. These results suggest that high-severity grade irAEs may occur early after switching to the new regimen.
一种新的纳武利尤单抗和帕博利珠单抗单药治疗方案已获批准，该方案的剂量是传统剂量的两倍，给药间隔更长（新方案）。在此，我们报告了大垣市立医院从传统方案转换为新方案早期阶段免疫相关不良事件（irAE）的发生率。2020年10月至2021年2月期间，37例患者转换为新方案：7例（18.9%）转换为纳武利尤单抗，5例（14.3%）转换为帕博利珠单抗。接受纳武利尤单抗治疗的7例患者中有2例发生irAE。1例患者在转换为新方案后第51天出现3级结肠炎，治疗中断。另1例患者在第72天出现3级肾上腺功能不全并住院。帕博利珠单抗治疗未观察到irAE。这些结果表明，转换为新方案后早期可能会出现高严重程度等级的irAE。
